2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 16: November 20, 2024 - Lighting the Path for IL-13’s Role in Atopic Dermatitis
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, November 20, 2024
8 PM ET / 5 PM PT
Lighting the Path for IL-13's Role in Atopic Dermatitis
This activity is supported by an educational grant from Lilly USA, LLC.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 21, 2024
November 21, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Recognize the burden of itch in chronic, recurrent flares in moderate-to-severe atopic dermatitis (AD) despite topical corticosteroid use
Discuss the role of interleukin (IL)-13 in the pathophysiology of the AD disease course
Differentiate biologic therapies targeting IL-13 based on their clinical profile
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mark Kaufmann, MD
Chief Medical Officer, Advanced Dermatology and Cosmetic Surgery
Clinical Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Peter Lio, MD
Clinical Assistant Professor of Dermatology Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board: Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi
Consultant: Abbvie, Arcutis, Dermavant, Galderma, Lilly, Regeneron, Sanofi
Speakers’ Bureau Honoraria: Abbvie, Arcutis, Dermavant, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi
Consultant: Apogee Therapeutics, Avita Medical, Biofrontera, Dermagnostix, Dermtech,Incyte, Novan, Novartis, Rise Healthcare, Rivera Consulting, UCB, Verrica
Ownership Interest (privately held): Modernizing Medicine, Molesafe
No relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.